How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC

Поделиться
HTML-код
  • Опубликовано: 8 фев 2025
  • Earn CME for related activities: www.naccme.com...
    In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell lung cancer (NSCLC).
    © 2016 Imedex, LLC.

Комментарии •